Cat. No.: DAB-0012084
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ile123 of human GNB3 protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | GNB3 |
| UniProt No. | P16520 |
| Gene ID | 2784 |
| Gene Description | Heterotrimeric guanine nucleotide-binding proteins, G proteins, transduce ligand binding to G protein-coupled receptors into intracellular responses. G proteins are comprised of 3 subunits, alpha, beta, and gamma. Upon activation of GPCRs, the receptor promotes the exchange of GDP to GTP of Gα, changing the confirmation of the switch regions within Gα. The receptor bound heterotimeric G protein is then released, and dissociates into the GTP-bound Gα monomer and the Gβ/Gγ heterodimer. Gα activates adenylyl cyclase, which converts ATP to the second messenger cAMP. Gα also activates phosphoinositide-specific phospholipase C, which catalyzes hydrolysis of the phospholipid of phosphatidylinositol 4, 5-biphosphate, releasing the second messengers IP3 and 1, 2-diacylglycerol. IP3 activates IP3 receptors to release Ca2+ from the ER. DAG is an activator of protein kinase C, which in turn activates the Erk1/2 pathway. The primary function of the Gβ/Gγ heterodimer is to inhibit Gα, although it may also activate second messengers or gate ion channels. Guanine nucleotide-binding protein b3 is an isoform of the b subunit. Research studies have shown that a polymorphism in the GNB3 gene, C825T, is associated with hypertension, obesity, and depression. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
